ArticlePLoS neglected tropical diseases2020
Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus.
Open access · goldAbstract readConsensus Statement
In one paragraph
Article in PLoS neglected tropical diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Facilitating the use of the target product profile in academic research: a systematic review.Journal of translational medicine · 2024Pooled it
- Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay.Nature communications · 2024Trial
- ELISA F29 -A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment.PLoS neglected tropical diseases · 2023Trial
- Conjugates of α-d-Galp-(1→3)-β-d-Galp for the serological diagnosis of Chagas disease.PLoS neglected tropical diseases · 2026Article
- Target product profile for the development of pediatric formulations of new drugs for the treatment of children with T. cruzi infection.PLoS neglected tropical diseases · 2026Review
- Quantitative Real-Time PCR for Trypanosoma cruzi Infection Diagnosis and Treatment Response Monitoring of Patients with Chagas Disease.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Reporter genes and transgenicFrontiers in medicine · 2025Review
- Impact of antiparasitic therapy on cardiovascular outcomes in chronic Chagas disease. A systematic review and meta-analysis.EClinicalMedicine · 2025Article
- Trypanocidal Treatment for Chronic Chagas Disease: Past, Present, and Future.Revista da Sociedade Brasileira de Medicina Tropical · 2025Review
- Changes in lipid abundance are associated with disease progression and treatment response in chronic Trypanosoma cruzi infection.Parasites & vectors · 2024Article
- Diversity of Chagas disease diagnostic antigens: Successes and limitations.PLoS neglected tropical diseases · 2024Review
- Consensus-driven target product profiles for curative sickle cell disease gene therapies.Molecular therapy. Methods & clinical development · 2024Review
- A Multi-Epitope Protein for High-Performance Serodiagnosis of Chronic Chagas Disease in ELISA and Lateral Flow Platforms.International journal of molecular sciences · 2024Article
- An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi-infected children. A retrospective cohort study.PLoS neglected tropical diseases · 2024Article
- Five-year serological and clinical evolution of chronic Chagas disease patients in Cochabamba, Bolivia.PLoS neglected tropical diseases · 2023Observational
- Validation of the NAT Chagas IVD Kit for the Detection and Quantification ofLife (Basel, Switzerland) · 2023Article
- Development and Application of an Assay to Evaluate the Anti-Parasitic Effect of Humoral Responses againstMicroorganisms · 2023Article
- Chagas disease treatment efficacy markers: experiences from a Phase III study with nifurtimox in children.Frontiers in parasitology · 2023Article
- Isothermal Nucleic Acid Amplification to Detect Infection Caused by Parasites of the Trypanosomatidae Family: A Literature Review and Opinion on the Laboratory to Field Applicability.International journal of molecular sciences · 2022Review
- An Updated View of theACS infectious diseases · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 17 institutions in 11 countries.
Julio Alonso-PadillaBarcelona Institute for Global Health (ISGlobal), Hospital Clínic-University of Barcelona, Barcelona, Spain.ORCID 0000-0003-4466-7969
Marcelo AbrilFundación Mundo Sano, Buenos Aires, Argentina.
Belkisyolé Alarcón de NoyaInstituto de Medicina Tropical, Universidad Central de Venezuela, Caracas, Venezuela.
Igor C AlmeidaBorder Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso, El Paso, Texas, United States of America.
Andrea AnghebenDepartment of Infectious-Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.
Tania Araujo JorgeInstituto Oswaldo Cruz, Fundaçao Instituto Oswaldo Cruz, Rio de Janeiro, Brazil.
Eric ChatelainDrugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland.
Monica EstevaInstituto Nacional de Parasitología "Dr. Mario Fatala Chaben", ANLIS "Dr. Carlos G. Malbrán", Ministerio de Salud, Buenos Aires, Argentina.
Joaquim GascónBarcelona Institute for Global Health (ISGlobal), Hospital Clínic-University of Barcelona, Barcelona, Spain.
Mario J GrijalvaCentro de Investigación para la Salud en América Latina (CISeAL), Pontificia Universidad Católica del Ecuador, Quito, Ecuador.
Felipe GuhlCentro de Investigaciones en Microbiología y Parasitología Tropical (CIMPAT), Universidad de los Andes, Bogotá, Colombia.
Alejandro Marcel Hasslocher-MorenoInstituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz-Ministério da Saúde, Brazil.
Manuel Carlos LópezInstituto de Parasitología y Biomedicina López Neyra (IPBLN), Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain.
Alejandro LuquettiHospital das Clínicas, Federal University of Goiás, Goiania, Brazil.
Oscar NoyaInstituto de Medicina Tropical, Universidad Central de Venezuela, Caracas, Venezuela.
María Jesús PinazoBarcelona Institute for Global Health (ISGlobal), Hospital Clínic-University of Barcelona, Barcelona, Spain.
Janine M RamseyInstituto Nacional de Salud Pública/CRISP, Tapachula, Chiapas, Mexico.
Isabela RibeiroDrugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland.
Andres Mariano RuizInstituto Nacional de Parasitología "Dr. Mario Fatala Chaben", ANLIS "Dr. Carlos G. Malbrán", Ministerio de Salud, Buenos Aires, Argentina.
Alejandro G SchijmanInstituto de Investigaciones en Ingeniería Genética y Biología Molecular (INGEBI), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
Sergio Sosa-EstaniDrugs for Neglected Disease initiative (DNDi) Latin America, Rio de Janeiro, Brazil.
M Carmen ThomasInstituto de Parasitología y Biomedicina López Neyra (IPBLN), Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain.
Faustino TorricoFundación CEADES; Universidad Mayor de San Simón, Cochabamba, Bolivia.
Maan ZreinInfynity Biomarkers, Lyon, France.ORCID 0000-0002-3301-4252
Albert PicadoFoundation for Innovative Diagnostics (FIND), Geneva, Switzerland.
Barcelona Institute for Global Health · ESCentral University of Venezuela · VEConsejo Nacional de Investigaciones Científicas y Técnicas · ARConsejo Superior de Investigaciones Científicas · ESDrugs for Neglected Diseases Initiative · CHMinisterio de Salud · ARFIND · CHFundação Oswaldo Cruz · BRFundación Pro Salud y Medio Ambiente · ARInstituto Nacional de Salud Pública · MXMinistério da Saúde · BROspedale Sacro Cuore Don Calabria · ITPontificia Universidad Católica del Ecuador · ECThe University of Texas at El Paso · USUniversidad de Los Andes · COUniversidade Federal de Goiás · BRUniversidad Mayor de San Simón · BO
Funding
UTEP Border Biomedical Research CenterU54MD007592 · NIMHD · UNIVERSITY OF TEXAS EL PASO · PI Bibiana Marie Mancera · 2019 to 2026
$35.1MNew chemotherapy regimens and biomarkers for Chagas diseaseU01AI129783 · NIAID · UNIVERSITY OF TEXAS EL PASO · PI ALMEIDA, IGOR C, GASCON, JOAQUIM · 2018 to 2024
$7.7MNIAID NIH HHS U01 AI129783NIMHD NIH HHS U54 MD007592
Abstract
PubMed holds no abstract for this paper.
Indexed as
Chagas DiseaseDiagnostic Tests, RoutineDrug MonitoringHumansTreatment OutcomeTrypanocidal AgentsTrypanocidal Agents
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.